Many patients with advanced melanoma eventually stop responding to PD-1 immunotherapy, and effective treatments are limited. Recent studies suggest that older chemotherapy drugs such as dacarbazine and temozolomide may work better after prior PD-1 therapy and can stimulate the immune system when combined with CTLA-4 blockade (ipilimumab). This review summarises clinical evidence and biological mechanisms supporting these combinations, including how chemotherapy-induced DNA damage can release tumour antigens, activate interferon pathways, and reawaken exhausted T cells. Because these regimens are relatively safe, inexpensive, and widely available, they may provide a realistic treatment option for patients in health systems where modern cell-based therapies are not accessible. Further clinical trials with integrated biomarker research are needed to identify which patients benefit most from this approach.
Urbonas et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: